Get started
Author

Monika Bratová

Observed names: M Bratova, M Bratová, M. Bratova, M. Bratová, MONIKA BRATOVA, Monika Bratova
ORCID: 0000-0001-9994-480X
Observed ORCID: 0000-0001-9994-480X
OpenAlex ID: A5018473625
Prediction of Postoperative Complications: Ventilatory Efficiency and Rest End-tidal Carbon Dioxide
2022 · Kristian Brat, Pavel Homolka, et al. · The Annals of Thoracic Surgery · 23
Ventilatory efficiency is superior to peak oxygen uptake for prediction of lung resection cardiovascular complications
2022 · Andrej Mazur, Kristian Brat, et al. · PLoS ONE · 19
PDF
Non-small Cell Lung Cancer as a Chronic Disease – A Prospective Study from the Czech TULUNG Registry
2019 · MONIKA BRATOVA, BARA KARLINOVA, et al. · In Vivo · 14
PDF
The risk of post-operative pulmonary complications in lung resection candidates with normal forced expiratory volume in 1 s and diffusing capacity of the lung for carbon monoxide: a prospective multicentre study
2022 · Ivan Cundrle, Zdenek Merta, et al. · ERJ Open Research · 10
PDF
Lung Cancer Versus “Young Cancer”: Is Non-Small Cell Lung Cancer in Young Patients a Different Entity?
2021 · Monika Bratova, Kristian Brat, et al. · Journal of Adolescent and Young Adult Oncology · 9
Real‐life effectiveness of first‐line anticancer treatments in stage IIIB / IV NSCLC patients: Data from the C zech TULUNG R egistry
2020 · Kristian Brat, Monika Bratova, et al. · Thoracic Cancer · 9
PDF
Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer
2023 · JIRI BLAZEK, PETR HOSEK, et al. · In Vivo · 7
PDF
Comedication with corticosteroids and nonsteroidal antiphlogistics does not affect PD-L1 expression in non-small cell lung cancer
2022 · Martin Svaton, Marie Drosslerova, et al. · Translational Cancer Research · 4
PDF
Laboratory Parameters Associated With Inflammation Do Not Affect PD-L1 Expression in Non-small Cell Lung Cancer
2022 · MARTIN SVATON, MARIE DROSSLEROVA, et al. · Anticancer Research · 3
Prognostic Value ofEGFRExon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer
2021 · JANA SKRICKOVA, MILOS PESEK, et al. · Anticancer Research · 3
Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study
2021 · MARTIN SVATON, MONIKA BRATOVA, et al. · Anticancer Research · 3
PDF
Nationwide Implementation of Neoadjuvant Nivolumab-Based Chemo-Immunotherapy for Resectable NSCLC: Surgical Outcomes from a Prospective Multicenter Study
2026 · Jiri Vachtenheim Jr, Fernando Casas-Mendez, et al. · Annals of Surgical Oncology · 2
PDF
Real‐World Data From a Molecular Tumor Board‐Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients?
2025 · Michal Eid, Markéta Bednaříková, et al. · Cancer Medicine · 2
PDF
Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer
2023 · Monika Bratova, Jana Skrickova, et al. · Journal of Cancer Research and Clinical Oncology · 2
PDF
Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?
2022 · MARTIN SVATON, MONIKA BRATOVA, et al. · Anticancer Research · 2
Pembrolizumab-induced hypothyreosis and subcutaneous bleeding
2021 · Pavel Polák, Jana Špeldová, et al. · Vnitřní lékařství · 2
Real-world PD-L1 testing, first-line therapy for advanced NSCLC, and first-line pembrolizumab monotherapy utilization and outcomes for metastatic NSCLC in the Czech Republic
2025 · Melissa Santorelli, Marika Chrápavá, et al. · Klinicka onkologie · 1
PDF
Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment
2021 · DANIEL KREJCI, PETR OPALKA, et al. · Anticancer Research · 1
Real-life effectiveness of first-line treatments in NSCLC patients stage IIIB/IV– data from the Czech TULUNG Registry
2020 · Kristian Brat, Monika Bratova, et al. · European Respiratory Journal · 1
273eP Nivolumab plus chemotherapy in the neoadjuvant treatment of NSCLC: Multicenter real-world data from the Czech Republic (NINA-CZ)
2026 · O. Bilek, L.F. Casas Mendez, et al. · ESMO Open
Actual possibilities of target therapy for Non-Small Cell Lung Cancer in Czech Republic
2025 · Monika Bratová · Onkologie
Quality of life in patients with lung cancer during the modern anticancer treatment - muticenter prospective data from the Czech Republic
2025 · Monika Bratová, Kristian Brat, et al. · European Respiratory Journal
The lung cancer patient quality of life during the first line of treatment – multicenter prospective data
2025 · Monika Bratová, Lenka Jakubíková, et al. · Klinicka onkologie
PDF
News in respiratory medicine
2023 · Kristián Brat, Martina Doubková, et al. · Vnitřní lékařství
PDF
Driver and actionable mutations in younger patients with lung cancer - are we searching properly?
2023 · Monika Bratova, Kristian Brat, et al. · Biomedical Papers
PDF
Works count: 44
Citation count: 117
H-index: 7
I10-index: 4
Year
Topic
Type